

## Curriculum Vitae

**Name** Jeeraphat Sirichaisinthop, M.D.  
**Sex** male  
**Nationality** Thai  
**Birth date** 18 August 1959  
**Marital status** single  
**Education** 1. M.D., Mahidol University, Bangkok, 1984  
 2. Certificate in Course on in vitro sensitivity test system for anti-malaria drug ( WHO/SEARO ), 1986  
 3. Certificate in Basic course on Malaria and Planning Malaria Control ( WHO/Italy/Thailand ), Phrabuddhabat Thailand, 1987  
 4. MPH., Hebrew University, Jerusalem Israel, 1989  
 5. Certified Board of Preventive Medicine (Epidemiology), 2006

**Office** Department of Disease Control, Ministry of Public Health  
 Mueang Nonthaburi, 11000, Thailand  
 Mobile +66 (81) 994 6647

### Professional experience

1984 – 1985 Internship, Saraburi Regional Hospital  
 1985 – 1995 Deputy Director of Malaria Regional Center 1 & Deputy Director of Malaria Training Center (MTC), Phrabuddhabat

1992 Chief of Epidemiological Branch, Malaria Division  
 1995 – 2002 Director of Office of Vector Borne Disease Control 1 & Director of Vector Borne Disease Training Center Phrabuddhabat

2003-present Director of Vector Borne Disease Training Center (aka Department of Disease Control Training Center since 2015)

2011-present Senior Expert for Vector Borne Disease, Department of Disease Control

### Special experience

1. In charge of in vitro and in vivo drug sensitivity monitoring, Malaria Region 1 Phrabuddhabat, 1985 – present

2. As a part-time instructor in various malaria training courses held in Malaria Training Center during 1986 – present on topics :  
 Malariology  
 Malaria Chemotherapy and Drug resistance  
 Epidemiology of Malaria, Surveillance and Evaluation  
 Analysis of Malaria situation and planning control  
 Development of Information System and Computerization  
 etc.

3. Instructor in an International Course on “Malaria Prevention and Control” (JICA) held in 2002, 2003 and 2005 on topics of Malaria Chemotherapy, Drug Resistance and Formulation of National Drug Policy, Malaria Surveillance and Early Warning System, Situation Analysis and Planning for Malaria Control.

4. Instructor in an International Course on “Basic Epidemiology” (JICA) held in 2005 on a topic of Clinical Epidemiology.
5. Technical Coordinator in Basic Course on Malaria and Planning Malaria Control ( WHO/Italy/Thailand ) held at MTC, 1995.
6. Visiting Advisor in Course on Management of Malaria Field Operation (ACT Malaria) 1997 – 2001.
7. Instructor in International Courses on “Management of Malaria Field Operation” (ACT Malaria) 2004 - 2009 topics: Malaria Field Situation Analysis and Case Management.
8. Course Manager and an Instructor in International Courses on “Malaria Prevention and Control” (TICA/JICA) held in 2005 - 2012 on topics of Malaria Epidemiology, Malaria Case Management, Drug Resistance and Monitoring, Formulation of National Drug Policy, Situation Analysis and Planning for Malaria Control.
9. Short term consultant for WHO in Bhutan Malaria Control Programme External Review Team, 23-30 March 2010, to assess the current policies, strategies, guidance, structures and performance in delivery of malaria control services in order to move the national programme from control to pre-elimination. Area of responsibility: diagnosis/treatment and quality assurance.

**Field of Specialization**

Malaria Epidemiology, Control and Chemotherapy

## Publication

1. A Comparative Study on Drug Response between 1,000 mg and 750 mg of Mefloquine to P. falciparum malaria. Sirichaisinthop J, Lawmepol A and Thimasarn K. Communicable Disease Journal 1992; 18(3): 190–195.
2. Monitoring in vivo studies on Effectiveness of Fansimef 750 mg on P. falciparum In Upper Central and Lower Northeastern Parts of Thailand in 1992. Ungkasrithongkul M, Sirichaisinthop J and Lawmepol A. Communicable Disease Journal 1992; 18(3): 182–189.
3. Comparative Study on Efficacy of Anti-malarial Drugs; FANSIIMEF® LARIAM® and MEPHAQUIN® at Malaria Clinic Maesot Tak Province. Lawmepol A, Sirichaisinthop J. and Thimasarn K. Communicable Disease Journal 1993; 19(3): 171–176.
4. In vivo Study of the Response of Plasmodium falciparum to Standard Mefloquine/Sulfadoxine/Pyrimethamine (MSP) Treatment among Gem Miners Returning from Cambodia. Thimasarn K, Sirichaisinthop J, Vijaykadga S et al. Southeast Asian Journal of Tropical Medicine and Public Health 1995, June; 26(2): 204–212.
5. Effective of Artesunate Combined with Mefloquine on falciparum malaria in Maesot Malaria Clinic, Tak Province. Sirichaisinthop J and Lawmepol A. Communicable Disease Journal 1996; 22(2): 112–117.
6. Study on Repellent Effect of Mozzie Buster against Malaria Vectors. Sirichaisinthop J and Bothijitti V. Communicable Disease Journal 1996; 22(3): 222–226.
7. A comparative study of artesunate and artemether in combination with mefloquine on multidrug resistant falciparum malaria in eastern Thailand. Thimasarn K, Sirichaisinthop J, Chanyakhun P, Palanant C, Rooney W. Southeast Asian J Trop Med Public Health 1997, September; 28(3): 465-471.
8. Complication with a 2 days Course of Artemether- Mefloquine in an area of Highly Multi-drug Resistant Plasmodium falciparum malaria. Na-Bangchang K, Congpuong K, Sirichaisinthop J, Suprakorb K and Karbwang J. British Journal of Clinical Pharmacology 1997; 43: 639-642.
9. Incidence of Anti-malarial Pretreatment and Drug Sensitivity in vitro in Multi-drug Resistant Plasmodium falciparum infection in Thailand. Congpuong K, Sirichaisinthop J, Tippawangkosol P, Suprakorb K, Na-Bangchang K, Tan-ariya P and Karbwang J Transactions of the Royal Society of Tropical Medicine and Hygiene 1998; 92: 84–86.
10. Investigations of incidence of pretreatment, drug sensitivity in vitro, and plasma levels of pyrimethamine in patients with multidrug resistant falciparum malaria following the three combination regimens of artemether/pyrimethamine. Tippawangkosol P, Na-Bangchang K, Ubalee R, Congpuong K, Sirichaisinthop J, Karbwang J. The Southeast Asian journal of tropical medicine and public health 1999; 30(2): 220-224.
11. Antimalarial drug combination policy: a caveat. Wongsrichanalai C, Thimasarn K, Sirichaisinthop J. The Lancet 2000, June; 355(Issue 9222): 2245-2247.
12. Application of Log-linear Model to Malaria Patients in Thailand Tiensuwan M, Lertprapai S, Sirichaisinthop J and Lawmepol A. Statistics in Medicine 2000; 19: 1931–1945.

13. Overview: Drug Resistant Malaria on the Thai-Myanmar and Thai-Cambodian Borders. Wongsrichanalai C, Sirichaisinthop J, Karwacki J J, Congpuong K, Miller R S, Pang L and Thimasarn K. Southeast Asian Journal Medicine and Public Health 2001, March; 32(1): 41–49.
14. Malaria Rapid Diagnostic Devices : Performance Characteristics of the ParaSight-F Device Determined in a Multisite Field Study. Forney J R, Magill A J, Wongsrichanalai C, Sirichaisinthop J, Bautista C, Heppner D G, Miller R S, Ockenhouse C F et al. Journal of Clinical Microbiology 2001, August; 39(8): 2884–2890.
15. Correlation of *in vivo* and *in vitro* responses of *Plasmodium vivax* to Chloroquine. Congpuong K, Na-Bangchang K, Tasanor O, Sirichaisinthop J, Wernsdorfer W H. Chula Med J 2002, August; 46(8): 639–647.
16. An *in vitro* system for assessing the sensitivity of *Plasmodium vivax* to chloroquine. Tasanor O, Noedl H, Na-Bangchang K, Congpuong K, Sirichaisinthop J, and Wernsdorfer W H. Acta Tropica 2002, July; 83(1): 49-61.
17. Dependence of Malaria Detection and Species Diagnosis by Microscopy on Parasite Density. McKenzie F E, Sirichaisinthop J, Miller S R, Gasser jr R A, Wongsrichanalai C. Am J Trop Med Hyg 2003; 69(4): 372-376.
18. Device for Rapid Diagnosis of Malaria: Evaluation of Prototype Assays That Detect *Plasmodium falciparum* Histidine-Rich Protein 2 and a *Plasmodium vivax*-Specific Antigen. Russ Forney J, Wongsrichanalai C, Magill A J, Craig L G, Sirichaisinthop J, Bautista C T, Miller R S, Ockenhouse C F, Kester K E, Aronson N E, Andersen E M, Quino-Ascurra H A, Vidal C, Moran K A, Murray C K, DeWitt C C, Heppner D G, Kain K C, Ballou W R, Gasser jr R A. J Clin Microbiol 2003, June; 41(6): 2358-2366.
19. Determining Cost-effectiveness and Cost Component of Three Malaria Diagnostic Models Being Used in Remote Non-microscope Areas. Bualombai P, Prajakwong S, Aussawatheerakul N, congpuong K, Sudathip S, Thimasarn K, Sirichaisinthop J, Indaratna K, Kidson C , Srisuphanand M. Southeast Asian J Trop Med Public Health 2003, June; 34(2): 322-333.
20. Comparison of artificial membrane feeding with direct skin feeding to estimate the infectiousness of *Plasmodium vivax* gametocyte carriers to mosquitoes. Sattabongkot J, Maneechai N, Phunkitchar V, Eikarat N, Khuntirat B, Sirichaisinthop J, Burge R, Coleman R E. The American journal of tropical medicine and hygiene 2003, November; 69(5): 529-535.
21. Blocking of transmission to mosquitoes by antibody to *Plasmodium vivax* malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. Sattabongkot J, Tsuboi T, Hisaeda H, Tachibana M, Suwanabun N, Rungruang T, Cao Y M, Stowers A W, Sirichaisinthop J, Coleman R, Torii M. Am J Trop Med Hyg 2003; 69(5): 536-541.
22. In-vitro interaction of tafenoquine and chloroquine in *Plasmodium falciparum* from northwestern Thailand. Vollnberg A, Prajakwong S, Sirichaisinthop J, Wiedermann G, Wernsdorfer G, Wernsdorfer W H. The Middle European Journal of Medicine 2003; 115(Suppl 3): 28-32.
23. Comparison of the *in-vitro* activity of amodiaquine and its main metabolite, monodesethyl-amodiaquine, in *Plasmodium falciparum*. Gerstner U, Prajakwong S, Wiedermann G, Sirichaisinthop J, Wernsdorfer

- G, Wernsdorfer W H. The Middle European Journal of Medicine (Wiener klinische Wochenschrift) 2003; 115(Suppl 3): 33-38.
24. In-vitro response of *Plasmodium falciparum* to the main alkaloids of Cinchona in northwestern Thailand. Knauer A, Sirichaisinthop J, Reinthaler F F, Wiedermann G, Wernsdorfer G, Wernsdorfer W H. The Middle European Journal of Medicine 2003; 115(Suppl 3): 39-44.
  25. *Plasmodium vivax* Transmission: Chances for Control? Sattabongkot J, Tsuboi T, Zollner G E, Sirichaisinthop J, Cui L. Trends in Parasitology 2004, April; 20(4): 192-198.
  26. Comparative study on the in vitro activity of lumefantrine and desbutyl-benflumetol in fresh isolates of *Plasmodium vivax* from Thailand. Pirker-Krassnig D K, Wernsdorfer G, Sirichaisinthop J, Rojanawatsirivet C, Kollaritsch H, Wernsdorfer WH. The Middle European Journal of Medicine 2004; 116(Suppl 4): 47-52.
  27. Drug Sensitivity of *Plasmodium falciparum* along the Thai-Myanmar border using the new field-deployable HRP2 *in vitro* assay. Attlmayr B, Kollaritsch H, Wernsdorfer W H, Miller R S, Sirichaisinthop J, Noedl H. The Middle European Journal of Medicine 2005; 117(Suppl 4): 35-38.
  28. Synergism of desbutyl-benflumetol and retinol against *Plasmodium falciparum in vitro*. Samal D, Rojanawatsirivet C, Wernsdorfer G, Kollaritsch H, Sirichaisinthop J, Wernsdorfer W H. The Middle European Journal of Medicine 2005; 117(Suppl 4): 39-44.
  29. In vitro activity of artemisinin alone and in combination with retinol against *Plasmodium falciparum*. Thriemer K, Wernsdorfer G, Rojanawatsirivet C, Kollaritsch H, Sirichaisinthop J, Wernsdorfer W H. The Middle European Journal of Medicine 2005; 117(Suppl 4): 45-48.
  30. Spatio-temporal distribution of *Plasmodium falciparum* and *P. vivax* malaria in Thailand. Zhou G, Sirichaisinthop J, Sattabongkot J, Jones J, Bjørnstad O N, Yan G, Cui L. The American Journal of Tropical Medicine and Hygiene (Am J Trop Med Hyg) 2005; 72(3): 256-262.
  31. Memory T cells protect against *Plasmodium vivax* infection. Jangpatarapongsa K, Sirichaisinthop J, Sattabongkot J, Liwang C, Montgomery S M, Looareesuwan S, Troye-Blomberg M, Udomsangpetch R. Microbes and Infection 2006; 8: 680-686.
  32. Clinical-parasitological response and in-vitro sensitivity of *Plasmodium vivax* to chloroquine and quinine on the western border of Thailand. Tasanor O, Ruengweerayut R, Sirichaisinthop J, Congpuong K, Wernsdorfer W H, Na-Bangchang K. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006; 100: 410-418.
  33. Fever in Patients with Mixed-Species Malaria. McKenzie F E, Smith D L, O'Meara W P, Forney J R, Magill A J, Permpnich B, Erhart L M, Sirichaisinthop J, Wongsrichanalai C and Gasser Jr R A. Clinical Infectious Diseases 2006; 42: 1713-1718.
  34. Sensitivity and specificity of an antigen detection ELISA for malaria diagnosis. Noedl H, Yingyuen K, Laoboonchai A, Fukuda M, Sirichaisinthop J, Miller S R. The American Journal of Tropical Medicine and Hygiene (Am J Trop Med Hyg) 2006; 75(Issue 6): 1205-1208.
  35. Pharmacodynamic interaction between atovaquone and other antimalarial compounds against *Plasmodium falciparum in vitro*. Lütgendorf C, Rojanawatsirivet C, Wernsdorfer G, Sirichaisinthop J,

- Kollaritsch H, Wernsdorfer W H. The Middle European Journal of Medicine 2006. October; 118(Suppl 3): 70-76.
36. In vitro interaction between artemisinin and chloroquine as well as desbutyl-benflumetol in *Plasmodium vivax*. Kyavar L, Rojanawatsirivet C, Kollaritsch H, Wernsdorfer G, Sirichaisinthop J, Wernsdorfer W H. The Middle European Journal of Medicine 2006; 118: 62-69.
  37. Meteorological, environmental remote sensing and neural network analysis of the epidemiology of malaria transmission in Thailand. Kiang R, Adimi F, Soika V, Nigro J, Singhasivanon P, Sirichaisinthop J, Leemingsawat S, Apiwathnasorn C, Looareesuwan S. Geospatial Health 2006; 1(1): 71-84.
  38. Gametocytemia in *Plasmodium vivax* and *Plasmodium falciparum* Infections. McKenzie F E, Wongsrichanalai C, Magill A J, Forney J R, Permpanich B, Lucas C, Erhart L M, O'Meara W P, Smith D L, Sirichaisinthop J and Gasser Jr R A. The Journal of Parasitology December 2006; 92(6): 1281-1285.
  39. Susceptibility to chloroquine, mefloquine and artemisinin of *Plasmodium vivax* in northwestern Thailand. Woitsch B, Wernsdorfer G, Congpuong K, Rojanawatsirivet C, Sirichaisinthop J, Wernsdorfer W H. The Middle European Journal of Medicine 2007; 119(Suppl 3): 76-82.
  40. Short-term in vitro culture of field isolates of *Plasmodium vivax* using umbilical cord blood. Udomsangpetch R, Somsri S, Panichakul T, Chotivanich K, Sirichaisinthop J, Yang Z, Cui L and Sattabongkot J. Parasitology International 2007, March; 56(1); 65-69.
  41. Production of erythropoietic cells in vitro for continuous culture of *Plasmodium vivax*. Panichakul T, Sattabongkot J, Chotivanich K, Sirichaisinthop J, Cui L and Udomsangpetch R. International Journal for Parasitology 2007, December; 37(14): 1551-1557.
  42. Synergistic interaction between atovaquone and retinol in *Plasmodium falciparum* in vitro. Exner B, Wernsdorfer G, Sirichaisinthop J, Rojanawatsirivet C, Kollaritsch H and Wernsdorfer W H. The Middle European Journal of Medicine 2007, November; 119(Suppl 3): 45-52.
  43. Synergistic interaction between monodesbutyl-benflumetol and retinol in *Plasmodium falciparum*. Parizek M, Sirichaisinthop J, Wernsdorfer G, Noedl H, Kollaritsch H, Wernsdorfer W H. The Middle European Journal of Medicine 2007, November; 119(Suppl 3): 53-59.
  44. Drug Sensitivity of *Plasmodium falciparum* and *Plasmodium vivax* in the area of Mae Sot, Tak Province, northwestern Thailand. Wernsdorfer WH, Congpuong K, Sirichaisinthop J, and Wernsdorfer G. Tropical Medicine and Health 2007; 35(1): 1-9.
  45. *Plasmodium vivax* parasites alter the balance of myeloid and plasmacytoid dendritic cells and the induction of regulatory T cells. Jangpatarapongsa K, Chootong P, Sattabongkot J, Chotivanich K, Sirichaisinthop J, Tungpradabkul S, Hisaeda H, Troye-Blomberg M, Cui L, Udomsangpetch R. European Journal of Immunology 2008; 38(10): 2697-2705.
  46. Synergism between quinine and retinol in fresh isolates of *Plasmodium falciparum*. Knauer A, Congpuong K, Wernsdorfer G, Reinthaler F F, Sirichaisinthop J and Wernsdorfer W H. The Middle European Journal of Medicine 2008; 120(Suppl 4): 69-73.

47. Pharmacodynamic interaction between 4-aminoquinolines and retinol in *Plasmodium falciparum* in vitro. Ley B, Wernsdorfer G, Frank C, Sirichaisinthop J, Congpuong K, Wernsdorfer W H. *The Middle European Journal of Medicine* 2008; 120(Suppl 4): 74-79.
48. Pharmacodynamic interaction between monodesbutyl-benflumetol and artemisinin as well as proguanil in *Plasmodium falciparum* in vitro. Raffelsberger J, Wernsdorfer G, Sirichaisinthop J, Kollaritsch H, Congpuong K, Wernsdorfer W H. *The Middle European Journal of Medicine* 2008; 120(19-20 Suppl 4): 90-94.
49. Interaction between lumefantrine and monodesbutyl-benflumetol in *Plasmodium falciparum* in vitro. Starzengruber P, Kollaritsch H, Sirichaisinthop J, Wernsdorfer G, Congpuong K, Wernsdorfer W H. *The Middle European Journal of Medicine* 2008; 120(19-20 Suppl 4): 85-89.
50. Immune response to *Plasmodium vivax* has a potential to reduce malaria severity. Chuangchaiya S, Jangpatarapongsa K, Chootong P, Sirichaisinthop J, Sattabongkot J, Pattanapanyasat K, Chotivanich K, Troye-Blomberg M, Cui L, Udomsangpetch R. *Clinical and Experimental Immunology* 2010; 160(2): 233-239.
51. Development of a reverse transcription-loop-mediated isothermal amplification (RT-LAMP) for clinical detection of *Plasmodium falciparum* gametocytes. Buates S, Bantuchai S, Sattabongkot J, Han ET, Tsuboi T, Udomsangpetch R, Sirichaisinthop J, Tan-ariya P. *Parasitol Int* 2010; 59: 414-20.
52. Synergism between pyronaridine and retinol in *Plasmodium vivax* in vitro. Riedl J, Wernsdorfer G, Congpuong K, Wiedermann U, Sirichaisinthop J, Wernsdorfer WH. *Wien Klin Wochenschr* 2010; 122 (Suppl 3): 66-70.
53. Synergism between mefloquine and artemisinin and its enhancement by retinol in *Plasmodium falciparum* in vitro. Kerschbaumer G, Wernsdorfer G, Wiedermann U, Congpuong K, Sirichaisinthop J, Wernsdorfer WH. *Wien Klin Wochenschr* 2010; 122 (Suppl 3): 57-60.
54. Malaria in the Greater Mekong Subregion: Heterogeneity and complexity. Cui L, Yan G, Sattabongkot J, Cao Y, Chen B, Chen X, Fan Q, Fang Q, Jongwutiwes S, Parker D, Sirichaisinthop J, Kyaw MP, Su XZ, Yang H, Yang Z, Wang B, Xu J, Zheng B, Zhong D, Zhou G. *Acta Trop* 2011 Mar 5.
55. Challenges and prospects for malaria elimination in the Greater Mekong Subregion. Cui L, Yan G, Sattabongkot J, Chen B, Cao Y, Fan Q, Parker D, Sirichaisinthop J, Su XZ, Yang H, Yang Z, Wang B, Zhou G. *Acta Trop* 2011 Apr 14.
56. Sensitivity of *Plasmodium vivax* to chloroquine, mefloquine, artemisinin and atovaquone in north-western Thailand. Treiber M, Wernsdorfer G, Wiedermann U, Congpuong K, Sirichaisinthop J, Wernsdorfer WH. *Wien Klin Wochenschr* 2011 Oct; 123 Suppl 1: 20-5.
57. *Plasmodium knowlesi* Malaria in humans and macaques, Thailand. Jongwutiwes S, Buppan P, Kosuvin R, Seethamchai S, Pattanawong U, Sirichaisinthop J, Putaporntip C. *Emerg Infect Dis* 2011 Oct; 17(10): 1799-806.
58. Evaluation of loop-mediated isothermal amplification (LAMP) for malaria diagnosis in a field setting. Sirichaisinthop J, Buates S, Watanabe

- R, Han ET, Suktawonjaroenpon W, Krasaesub S, Takeo S, Tsuboi T, Sattabongkot J. *Am J Trop Med Hyg* 2011 Oct; 85(4); 594-596.
59. Natural infection of *Plasmodium falciparum* induces inhibitory antibodies against gametocyte development in human hosts. Tonwong N, Tsuboi T, Iriko H, Prachumsri J, Sirichaisinthop J, Takeo S, Udomsangpetch R. *Jpn J Infect Dis* 2012 Mar; 65(2): 152-6.
60. Longitudinal in vitro surveillance of *Plasmodium falciparum* sensitivity to common anti-malarials in Thailand between 1994 and 2010. Parker D, Lerdprom R, Srisatjarak W, Yan G, Sattabongkot J, Wood J, Sirichaisinthop J, Cui L. *Malar J.* 2012; 11(1): 290.
61. Genetic diversity and lack of artemisinin selection signature on the *Plasmodium falciparum* ATP6 in the Greater Mekong Subregion. Miao M, Moji H, Mu J, Nakazawa S, Parker D, Pongvongsa T, Putaporntip C, Prachumsri J, Sirichaisinthop J, Su X, Wang Z, Xangsayarath P, Yan G, Yang Z, Yuan L, Tuong T, Jongwutiwes S, Kaneko O, Kyaw M, Abe T, Cui L. *PloS one* 2013; 8(3): e59192.
-